Single-Agent Tislelizumab, an Anti-PD-1 Antibody: Results from a Phase 1 Expansion Cohort in NSCLC Patients

被引：1
|
作者：
Barlow, P. [1 ]
Jameson, M. [2 ,3 ]
Lin, C. [4 ]
Wu, J. [5 ]
Pirzkall, A. [5 ]
Lee, J. [6 ]
机构：
[1] Auckland City Hosp, Auckland, New Zealand
[2] Waikato Hosp, Reg Canc Ctr, Hamilton, New Zealand
[3] Univ Auckland, Waikato Clin Campus, Hamilton, New Zealand
[4] Natl Taiwan Univ Hosp, Taipei, Taiwan
[5] Beigene Usa Inc, San Mateo, CA USA
[6] Seoul Natl Univ, Bundang Hosp, Seongnam Si, Gyeonggi Do, South Korea
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
tislelizumab; NSCLC; Anti-PD-1;
D O I：
10.1016/j.jtho.2019.08.1538
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.04-33
引用
收藏
页码：S721 / S721
页数：1
相关论文
共 50 条
  • [21] Phase II Study of the Anti-PD-1 Antibody Pembrolizumab in Patients with Malignant Mesothelioma
    Kindler, Hedy Lee
    Karrison, Theodore
    Khattri, Arun
    Zuo, Zhixiang
    Sulai, Nanna
    Rose, Buerkley
    Ahmad, Mehwish I.
    Armato, Samuel
    Salgia, Ravi
    Seiwert, Tanguy
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S630 - S630
  • [22] The Impact of Neutrophil/Lymphocyte Ratio as the Predictive Marker to Anti-PD-1 Antibody Treatment in NSCLC Patients
    Tanimura, K.
    Yamada, T.
    Tamiya, N.
    Kaneko, Y.
    Uchino, J.
    Takayama, K.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2012 - S2012
  • [23] Safety and efficacy of vibostolimab, an anti-TIGIT antibody, plus pembrolizumab in patients with anti-PD-1/PD-L1-naive NSCLC
    Niu, J.
    Nagrial, A.
    Voskoboynik, M.
    Chung, H. C.
    Lee, D. H.
    Ahn, M-J.
    Bauer, T. M.
    Jimeno, A.
    Chung, V.
    Mileham, K. F.
    Chartash, E.
    Chen, D.
    Healy, J.
    Rajasagi, M.
    Maurice-Dror, C.
    ANNALS OF ONCOLOGY, 2020, 31 : S891 - S892
  • [24] A Phase 1B Study of the Anti-PD-1 Monoclonal Antibody, Tislelizumab, in Combination with the Parp Inhibitor, Pamiparib, in Advanced Solid Tumors
    Friedlander, M.
    Meniawy, T.
    Markman, B.
    Mileshkin, L. R.
    Harnett, P.
    Millward, M.
    Lundy, J.
    Freimund, A. E.
    Norris, C.
    Wu, J.
    Paton, V.
    Wang, L.
    Gao, B.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 58 - 59
  • [25] Tolerability and antitumor activity of cemiplimab, a human monoclonal anti-PD-1, in patients with non-small cell lung cancer (NSCLC): Interim data from phase 1 dose escalation and NSCLC Expansion Cohort.
    Garcia, Victor Moreno
    Calvo, Emiliano
    Olmedo Garcia, Maria Eugenia
    Martin, Marta Gil
    Aljumaily, Raid
    Papadopoulos, Kyriakos P.
    Rosen, Lee S.
    Rietschel, Petra
    Mohan, Kosalai Kal
    Li, Jingjin
    Stankevich, Elizabeth
    Rowlands, Tracey
    Feng, Minjie
    Fury, Matthew G.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [26] Anti-PD-1 antibody monotherapy or anti-PD-1 antibody combination with chemotherapy treated non-small cell lung cancer (NSCLC) patients with EGFR mutation: A retrospective analysis.
    Yu, Shaorong
    Hu, Ran
    Shi, Meiqi
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [27] A phase 1 study of the OX40 agonist, BGB-A445, with or without tislelizumab, an anti-PD-1 monoclonal antibody, in patients with advanced solid tumors
    Desai, Jayesh
    Davar, Diwakar
    Deva, Sanjeev
    Gao, Bo
    Liu, Tianshu
    Matos, Marco
    Meniawy, Tarek
    O'Byrne, Kenneth John
    Sun, Meili
    Voskoboynik, Mark
    Yang, Kunyu
    Yu, Xinmin
    Chen, Xin
    Dong, Yan
    Giovinazzo, Hugh
    Leaw, Shiangjiin
    Patel, Deepa
    Rahman, Tahmina
    Wu, Yanjie
    Day, Daphne
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [28] Efficacy and safety results from the phase II study of Timdarpacept in combination with tislelizumab, in prior anti-PD-1 failed classical Hodgkin lymphoma
    Song, Y.
    Zhou, K.
    Hou, S.
    Zhang, Y.
    Li, F.
    Yang, W.
    Yi, T.
    Lin, N.
    Liu, X.
    Meng, W.
    Wang, Z.
    Lu, Q.
    Tian, W.
    Zhu, J.
    ANNALS OF ONCOLOGY, 2024, 35 : S600 - S600
  • [29] Anti-PD-1 antibody treatment for melanoma
    Ribas, Antoni
    Kirkwood, John M.
    Flaherty, Keith T.
    LANCET ONCOLOGY, 2018, 19 (05): : E219 - E219
  • [30] Vibostolimab, an anti-TIGIT antibody, as monotherapy and in combination with pembrolizumab in anti-PD-1/PD-L1-refractory NSCLC
    Ahn, M-J.
    Niu, J.
    Kim, D-W.
    Rasco, D.
    Mileham, K. F.
    Chung, H. C.
    Vaishampayan, U. N.
    Maurice-Dror, C.
    Lo Russo, P.
    Golan, T.
    Chartash, E.
    Chen, D.
    Healy, J.
    Rajasagi, M.
    Lee, D. H.
    ANNALS OF ONCOLOGY, 2020, 31 : S887 - S887
12345